Multicenter Phase II Clinical Trial of Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy for Patients With High-Grade Upper Tract Urothelial Carcinoma.
Jonathan A ColemanWesley YipNathan C WongDaniel D SjobergBernard H BochnerGuido DalbagniS Machele DonatHarry W HerrEugene K ChaTimothy F DonahueEugene J PietzakAbraham Ari HakimiKwanghee KimHikmat A Al-AhmadieH Alberto VargasRicardo G AlvimSoleen GhafoorNicole E BenfanteAnoop M MeraneySteven J ShichmanJeffrey M KamradtSuresh G NairAngelo A BaccalaPaul PalycaBradley W LashMuhammad A RizviScott K SwansonAntonio F MuinaAndrea B ApoloGopakumar V IyerJonathan E RosenbergMin Yuen TeoDean F BajorinPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
NAC with split-dose GC for high-risk UTUC is a well-tolerated, effective therapy demonstrating evidence of pathologic response that is associated with favorable survival outcomes. Given that these survival outcomes are superior to historical series, these data support the use of NAC as a standard of care for high-risk UTUC, and split-dose GC is a viable option for NAC.
Keyphrases
- neoadjuvant chemotherapy
- phase ii
- clinical trial
- transcription factor
- locally advanced
- high grade
- open label
- double blind
- lymph node
- sentinel lymph node
- rectal cancer
- phase iii
- genome wide analysis
- placebo controlled
- squamous cell carcinoma
- healthcare
- palliative care
- low grade
- gas chromatography
- electronic health record
- radiation therapy
- quality improvement
- affordable care act
- stem cells
- big data
- study protocol
- randomized controlled trial
- pain management
- early stage
- health insurance
- mesenchymal stem cells
- high resolution
- bone marrow
- mass spectrometry
- cross sectional
- deep learning